Phase 3 N=25 Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers
Poliomyelitis
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 4; 0; 5; 0 Subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=837 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
Psoriasis
Primary: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) in the Guselkumab Group Compared to the Placebo…
Phase 3 N=881 Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults
HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-defined Snapshot Algorithm — 90.0; 92.0 percentage of participants — p=0.35
Phase 3 N=642 Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer Metastatic
Primary: Percentage of Participants With an Objective Response — 39.0; 41.7 percentage of participants
Phase 3 N=68 Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion
Non-Ischemic Central Retinal Vein Occlusion
Primary: The Primary Efficacy Endpoint is the Total Number of PRN Bevacizumab Intravitreal Injections Through 24 Weeks — 5; 19; 13; 11 Participants — p=0.00002
Phase 3 N=105 Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection
Hepatitis C Virus (HCV)
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 89.5 percentage of participants
Phase 3 N=86 Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects
Infections, Meningococcal
Primary: Number of Subjects With a Vaccine Response for Serum Bactericidal Assay Using Rabbit Complement Against Neisseria Meningitides Serogroups A, C, W-135 and Y (rSBA-MenA…
Phase 3 N=135 Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection
Liver Cancer
Primary: Postoperative Complications — 42; 45; 24; 24 Participants
Phase 3 N=34 The Effect of Pseudoephedrine on Rhinitis and Sleep
Rhinitis · Sleep
Primary: Improvement of Sleep Associated With the Use of Pseudoephedrine as Compared to the Placebo
Phase 3 N=1,100 Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF
Infertility
Primary: Clinical Pregnancy Rate After One Cycle of Treatment - ITT Population — 114; 138; 435; 413 Participants
Phase 3 N=530 DHEA Against Vaginal Atrophy - Safety Study of 12 Months
Vaginal Atrophy
Primary: Long-term Safety of Intravaginal Prasterone (DHEA): Endometrium — 421; 36 Participants
Phase 3 N=740 Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 — 12.4; 38.7; 39.2…
Phase 3 N=489 Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)
Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12) — 94.2 percentage of participants — p=<0.001
Phase 3 N=165 SMART-SF Radiofrequency Ablation Safety Study
Atrial Fibrillation
Primary: Percentage of Participants With Early Onset Primary Adverse Events — 2.6 Percentage of participants
Phase 3 N=220 Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy
Asthma
Primary: Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control — 75.00; 75.00; 25.00 Percent — p=<0.001